Trial · NCT03738150
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks | Sotatercept | 1.28 | Standard Deviation 2.628 | mL/min/kg | |
| Change From Baseline in Right Ventricular Stroke Volume (RV SV) at 24 Weeks | Sotatercept | -27.306 | Standard Deviation 26.5786 | mL | |
| Change From Baseline in Right Ventricular End-Systolic Volume (RV ESV) at 24 Weeks | Sotatercept | -39.151 | Standard Deviation 22.5544 | mL | |
| Change From Baseline in Right Ventricular End-Diastolic Volume (RV EDV) at 24 Weeks | Sotatercept | -66.459 | Standard Deviation 37.3311 | mL | |
| Percent Change From Baseline in Right Ventricular Ejection Fraction (RV EF) at 24 Weeks | Sotatercept | -1.3 | Standard Deviation 8.48 | Percent change | |
| Change From Baseline in Right Ventricular Stroke Volume Index (RV SVI) at 24 Weeks | Sotatercept | -15.073 | Standard Deviation 14.8219 | mL/m^2 | |
| Change From Baseline in Right Ventricular (RV) Mass at 24 Weeks | Sotatercept | -6.240 | Standard Deviation 13.3558 | grams | |
| Change From Baseline in Ventilatory Efficiency (VE/VCO2 Slope) at 24 Weeks | Sotatercept | -8.87 | Standard Deviation 12.298 | Unitless | |
| Change From Baseline in Cardiac Index at 24 Weeks | Sotatercept | 0.411 | Standard Deviation 1.1944 | Liter/min/m^2 | |
| Change From Baseline in Mean Pulmonary Arterial Pressure at 24 Weeks | Sotatercept | -14.9 | Standard Deviation 13.22 | mmHg | |
| Change From Baseline in Arteriovenous O2 Content Difference (Ca-vO2) at 24 Weeks | Sotatercept | 0.63 | Standard Deviation 2.131 | mL/100 mL | |
| Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks | Sotatercept | -305.728 | Standard Deviation 313.9827 | dynes*sec/cm^5 | |
| Change From Baseline in 6-Minute Walk Distance (6MWD) at 24 Weeks | Sotatercept | 66.35 | Standard Deviation 85.659 | meters | |
| Change From Baseline in Concentration of Amino-Terminal Brain Natriuretic Propeptide (NT-proBNP) at 24 Weeks | Sotatercept | -623.1 | Standard Deviation 840.56 | pg/mL | |
| Change From Baseline in WHO (World Health Organization) Functional Class at 24 Weeks | Sotatercept | -0.76 | Standard Deviation 0.903 | WHO functional class | |
| Number of Participants With One or More Adverse Events (AEs) | Sotatercept | 20 | Participants | ||
| Number of Participants Who Experienced One or More Events Indicative of Clinical Worsening of Pulmonary Arterial Hypertension (PAH) | Sotatercept | 1 | Participants | ||
| Observed Trough Concentration (Ctrough) of Sotatercept at Cycle 9 | Sotatercept | 5884.79 | Standard Deviation 2933.77 | ng/mL | |
| Maximum Plasma Concentration (Cmax) of Sotatercept at Cycle 9 | Sotatercept | 9732.785 | Standard Deviation 2852.373 | ng/mL | |
| Minimum Plasma Concentration (Cmin) of Sotatercept at Cycle 9 | Sotatercept | 6234.303 | Standard Deviation 2466.046 | ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03738150/results